Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib study of gevokizumab (VPM087) with standard therapies in metastatic colorectal, gastroesophageal, and renal cell carcinoma
jRCT2080224642Phase 1Completed
- Sponsor
- Novartis
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of gevokizumab in metastatic colon cancer (mCRC), esophagogastric junction cancer and metastatic renal cell carcinoma (mRCC) (5 arms), sponsored by Novartis. Started Apr 2019; status: completed.
02
Drugs
gevokizumab
03
Conditions
metastatic colon cancer (mCRC)esophagogastric junction cancermetastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on jRCT2080224642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224642.